Pharmacokinetics and Safety of the Tyrosine Kinase 2 Inhibitor Deucravacitinib in Healthy Chinese Subjects

Jing, S; Lin, Y; Dockens, R; Marchisin, D; He, B; Girgis, IG; Chimalakonda, A; Murthy, B; Aras, U

Aras, U (通讯作者)，Bristol Myers Squibb, 3551 Lawrenceville Rd, Princeton, NJ 08540 USA.

DERMATOLOGY AND THERAPY, 2023; 13 (12): 3153

Abstract

IntroductionDeucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, blocks cytokine signaling involved in psoriasis pathogenesis.......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索